Scientific Publications Database

Article Title: Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Overall survival (OS) results from
Authors: Campone, Mario; Im, Seock-Ah; Iwata, Hiroji; Clemons, Mark; Ito, Yoshinori; Awada, Ahmad; Chia, Stephen; Jagiello-Gruszfeld, Agnieszka; Pistilli, Barbara; Tseng, Ling-Ming; Hurvitz, Sara; Masuda, Norikazu; Cortes, Javier; De laurentiis, Michele; Arteaga, Carlos L.; Jiang, Zefei; Jonat, Walter; Sellami, Dalila; El-Hashimy, Mona; Le Mouhaer, Sylvie; Sankaran, Banu; Bourdeau, Laurence; Baselga, Jose
Journal: CANCER RESEARCH Volume 78 Issue 4
Date of Publication:2018
Abstract:
.